LTL Pharma Looks to Acquire More Off-Patent Brands with Dellegra as a Catalyst

LTL Pharma CEO Jiro Mizukawa LTL Pharma has sealed a deal earlier this year to take over Sanofi’s anti-allergy agent Dellegra (fexofenadine + pseudoephedrine) in Japan, and it wants to capitalize on the product to build a track record in...read more